| Analysis | Samples | Factors | Units |
|---|---|---|---|
| None (Direct infusion) NEGATIVE ION MODE | TFA-T10 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T11 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T12 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T13 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T14 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T8 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T9 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T1 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T2 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T3 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T4 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T5 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T6 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T7 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T50 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T51 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T52 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T53 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T54 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T55 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T56 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T43 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T44 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T45 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T46 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T47 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T48 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T49 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T36 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T37 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T38 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T39 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T40 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T41 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T42 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T22 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T23 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T24 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T25 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T26 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T27 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T28 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T29 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T30 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T31 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T32 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T33 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T34 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T35 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T15 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T16 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T17 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T18 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T19 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T20 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-T21 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon | mg/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT10 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT11 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT12 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT13 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT14 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT8 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT9 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT1 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT2 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT3 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT4 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT5 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT6 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT7 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT50 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT51 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT52 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT53 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT54 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT55 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT56 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT43 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT44 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT45 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT46 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT47 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT48 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT49 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT36 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT37 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT38 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT39 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT40 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT41 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT42 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT22 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT23 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT24 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT25 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT26 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT27 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT28 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT29 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT30 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT31 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT32 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT33 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT34 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT35 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT15 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT16 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT17 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT18 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT19 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT20 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | EicoT21 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon | ng/g tissue |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P10 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P11 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P12 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P13 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P14 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P8 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P9 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P1 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P2 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P3 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P4 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P5 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P6 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P7 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P50 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P51 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P52 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P53 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P54 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P55 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P56 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P43 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P44 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P45 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P46 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P47 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P48 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P49 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P36 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P37 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P38 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P39 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P40 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P41 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P42 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P22 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P23 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P24 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P25 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P26 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P27 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P28 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P29 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P30 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P31 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P32 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P33 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P34 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P35 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P15 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P16 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P17 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P18 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P19 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P20 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | TFA-P21 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma | mg/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP10 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP11 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP12 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP13 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP14 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP8 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP9 | Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP1 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP2 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP3 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP4 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP5 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP6 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP7 | Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP50 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP51 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP52 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP53 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP54 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP55 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP56 | Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP43 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP44 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP45 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP46 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP47 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP48 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP49 | Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP36 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP37 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP38 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP39 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP40 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP41 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP42 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP22 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP23 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP24 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP25 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP26 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP27 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP28 | Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP29 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP30 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP31 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP32 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP33 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP34 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP35 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP15 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP16 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP17 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP18 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP19 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP20 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
| None (Direct infusion) NEGATIVE ION MODE | EicoP21 | Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma | ng/mL |
Return to study ST002354 main page
Download data matrix(Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. None (Direct infusion) NEGATIVE ION MODE)
Download data matrix(Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. None (Direct infusion) NEGATIVE ION MODE)
Download data matrix(Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. None (Direct infusion) NEGATIVE ION MODE)
Download data matrix(Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. None (Direct infusion) NEGATIVE ION MODE)
- Metabolomics Workbench
|